Medication for stimulation of metabolic processes and growth activity of calves

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and can be applied in animal-breeding for stimulation of metabolic processes, and growth activity of calves. Medication for stimulation of metabolic processes and growth activity of calves includes succinic acid as energetic stimulator, with application of citric acid as activator of succinic acid, beetroot molasses as carbon component, and methionine and sodium chloride as stimulators of digestion system.

EFFECT: application of invention makes it possible to ensure expressed acceleration of growth energy in early postnatal period.

3 tbl, 2 ex

 

The invention relates to veterinary medicine and can be used in animal husbandry to stimulate metabolism, growth activity, prevention of gastrointestinal diseases and enhance General resistance of the organism of newborn animals.

The issues of preservation of newborn animals and increase the resistance of the organism calves are problematic tasks of veterinary science and practice. Modern livestock intensification has led to a number of negative factors, an extremely negative impact on the health of newborns. Born offspring initially has defects in metabolic and immune systems, which is manifested by malnutrition, retarded growth and development, immune deficiency, high levels of gastro-intestinal diseases.

For the prevention and treatment of the above-mentioned pathophysiological States and diseases in newborns was widely practised by various stimulators of metabolic and immune processes, tools, chemotherapy and antibiotic therapy. In the vast majority of these funds are used as monotherapies. The narrow focus of these funds is often gives a positive result when used in the system of ensuring the health and safety of newborns.

Currently in medicine and veterinary medicine wide when�enemie get drugs metabolic action on the basis of succinic acid.

Absolute harmlessness of succinic acid and its derivatives, the ability to have a positive effect even at the absolute lowest doses, to increase the effects of other drugs, making it very valuable in the development of complex products, feed and food additives.

The closest in composition to the drug to enhance the metabolic processes of immunity in farm animals, selected as a prototype, is "Privaten" (patent RF №2259832 from 10.09.2005). The composition of the drug Privaten includes the following components: weight %: riboxinum - 10,0-40,0; calcium glycerophosphate 30,0-40,0; vitamin b 12-0,02-0,04; ascorbic acid 2-4; citric acid-2; succinic acid 2-4; folic acid 1-2, fructose 5-10, glucose and 100.

The inclusion of the drug in animal feeding and the birds proved to be very effective. The drug markedly improves the metabolic processes, increases resistance to infectious diseases.

However, the drug contains in its composition components, in particular glucose, fructose, considered to be quite scarce, which significantly restricts its production.

The object of the present invention to provide a drug for the stimulation of metabolism and growth activity dairy calves during rearing.

To solve this problem is proposed �repeat with energomehanicheskie activity.

The main energetic component in the drug is succinic acid. Succinic acid is a potent stimulator of energy production in cells. As is known, the process of digestion was associated with a significant energy cost. In this regard, succinic acid, providing energy to the cells of the mucosa of the stomach, improves digestion. As a result more fully are found in milk protein, mineral and vitamin substances.

Succinic acid and its salts have a broad spectrum of effects on various mechanisms of regulation of metabolic activity of cells, which is especially important with various pathophysiological conditions. The object of the action of the YAK are the cells and tissues in a state of excitement or pathologically altered. Stimulating effect of succinic acid is particularly pronounced in the weakening of the body and disease.

The absolute harmlessness of the YAK and its compounds, having the ability to have a positive effect in low dosages, making it very attractive when developing a new generation of so-called "smart" drugs (Kondrashova M. N., 1996).

To enhance the pharmacological effect of succinic acid in the composition is injected citric acid. Citric acid is an activator of succinic acid cycle tricarboxylic acid�t Krebs. Complex compound succinic and citric acids were implemented in the well known tablet drug Limonta (Patent RF №2039556).

As carbohydrate food and partly to remedy the unpleasant taste of succinic acid in the ingredients included sugar beet molasses. Beet molasses is widely used in the livestock industry as a source of carbohydrates, improve the taste of feed.

To enhance metabolic and hepatoprotective activity of the drug included methionine. Methionine is essential amino acids and is a critical amino acid for newborn animals because their digestive system is unable to synthesize nitrogen-containing substances of the feed. With the shortage of methionine anemia is often observed, fat and toxic degeneration of the liver. In the body methionine activates a number of enzymes, hormones, vitamin B12folic and ascorbic acids. Many of the processes of neutralization of toxins in the liver also occur with the participation of methionine.

As a means of improving the digestion in the drug included sodium chloride in an amount of 2% by volume. The metabolism of sodium chloride is closely associated with metabolic processes, disturbed in diarrhea, metabolic acidosis. These basic pathophysiological States in a �different degrees of severity observed in calves at an early age.

The proposed composition allows to obtain metabolic, energetically effects.

The quantitative content of the components producing the above mentioned effects found experimentally and are illustrated by the following experience.

For the experiment were prepared for the experimental series of formulations containing 100 ml of solution:

1 g of succinic acid, 2 g of sodium chloride and 30 ml of beet molasses (recipe 1);

1 g of succinic acid, 2 g of sodium chloride 30 ml beet molasses, 1 g of methionine (recipe 2);

1 g of succinic acid, 2 g of sodium chloride, 30 ml of beet molasses, 1 g of methionine, 0.1 g of citric acid (recipe 3);

1 g of succinic acid (control);

Assessment of growth activity conducted on mice with initial body weight of 10-11 g. each group contained 5 mice. The above formulations were administered orally by force, in a volume of 1 ml, three times with an interval of 24 hours. 10 days later, experimental mice were weighed.

The weighing results are presented in table 1.

The results of the trial show that a pronounced strengthening of growth activity when included in the composition of succinic acid and molasses.

Technology of production of metabolic composition is illustrated by the following examples.

Example 1. A suspension containing 10 g of succinic acid and 2 g of sodium chloride is introduced into the flask with 200 ml of pure�Oh tap water. Heated until complete dissolution of succinic acid, after which make a total of 4 grams of methionine. In parallel in an enamel bowl pour 500 ml of clean tap water. In it is poured into 300 ml of heated to 30-35oWith beet molasses. The contents of the flask poured into a solution with beet molasses. Thoroughly mixed, Packed in plastic bottles for food purposes with a capacity of 0.5 liters, sealed lids.

Example 2. Use the same technology as that in example 1, adding a hitch with succinic acid and 1 g of citric acid.

Received versions of the drugs that we designate as "amber biostimulant" for oral use, were tested on newborn calves 2-3 days of age with clinically severe symptoms of malnutrition.

Evaluation of the influence of the drug to stimulation of growth activity, hematological and biochemical processes in calves-lipotropics.

In a comparative test tested three versions of the composition. Composition according to recipe 1 (succinic acid - 5 g, sodium chloride 10 g, beet molasses - 150 ml); the composition according to recipe 2 (succinic acid-5 g, sodium chloride 10 g, beet molasses - 150 ml methionine 2 g); composition according to recipe 3 (succinic acid-5 g, sodium chloride 10 g citric acid 0.5 g, beet molasses - 150 ml methionine 2 g); control - a composition according to recipe 4 (succinic acid - 5 g). Minnesotawe prepared based on 500 ml of solution and was vipavadee three consecutive days in 500 ml single dose, once a day. As control served a similar group of calves-lipotropics. Metabolic activity was assessed by the results of studies of serum on the basic hematological and biochemical parameters.

The results are presented in table 2.

According to the results of biochemical test set a more pronounced effect of compounds 2 and 3 (with the addition of methionine) on hematopoiesis (red blood cell count and their saturation hemoglobin), protein metabolism and mineral metabolism compared with control and composition without the addition of methionine.

Stimulation of metabolic processes favorable effect on the energy of growth (table 3).

Thus, based on a series of pilot experiments established that the subject the composition of beet molasses and succinic acid with the addition of methionine, citric acid and sodium chloride provides a pronounced acceleration energy of growth in the early postnatal period.

Table 1
The influence of metabolic compounds on the growth activity of mice
Drugthe average weight of mice (g)
background after 10 days
Yak+ beet molasses10,4+0,217,9+0,4
Yak+ beet molasses+methionine10,4+0,318,2+0,4
Yak+ beet molasses+methionine +citric acid10,3+0,218,4+0,2
Yak (control)10,4+0,213,1+0,4

Table 2
The influence of tested compounds on the metabolic processes of calves-lipotropics
DrugHemoglobin, g/lErythrocytes, mln/cm3Protein, g/lCalcium mmol/lPhosphorus mmol/l
By the prescription 178,24±3,12 85,6±2,363,9±0,4 4,4±0,2The 61.8±2,4 65,7±2,21,56±0,11 2,78±0,151,29±0,16 1,62±0,23
By the prescription 279,62�2,75 89,19±2,15 3,9±0,2 4,6±0,161,2±2,3 67,3±2,3A 1.54±0,09 2,67±0,121,31±0,12 1,65±0,18
By the prescription 378,56±2,84 90,26±2,543,9±0,3 4,6±0,261,4±2,5 70,2±2,3A 1.54±0,06 2,82±0,141,33±0,14 1,67±0,19
Control
Yak
78,56±2,42 82,8±2,563,9±0,2 4,2±0,360,8±2,4 62,7±2,61,59±0,11 1,67±0,081,34±0,17 1,58±0,13
Note: numerator - background indicators; denominator - indicators for 10 days

Table 3
The influence of tested compounds of the drug to stimulation of the growth activity of calves-lipotropics
GroupDrugBody weight (kg)Daily gains (g)
In the beginning of the experimentAfter 14 days
1By the prescription 122,5±2,332,4±2,7720
2By the prescription 223,1±2,433,5±3,1780
3By the prescription 323,1±2,534,1±2,4790
4Control24,5±2,330,8±2,9490

The drug for stimulation of metabolism and growth activity of calves, including as an energy stimulant succinic acid, characterized in that as activator of succinic acid using citric acid as a carbohydrate component beet molasses, stimulant of the digestive system methionine and sodium chloride, with the following ratio of components based on 0.5 liters of solution
Succinic acid 5.0 g
Citric acid 0,5 g
Beet molasses 150,0 ml
Methionine 2.0 g
Sodium chloride 10.0 g
The rest of the water.



 

Same patents:

FIELD: medicine.

SUBSTANCE: cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +40±1-2°C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days.

EFFECT: higher body adaptability by increasing antioxidant activity and reducing a rate of lipid peroxidation products accumulation with underlying thermal exposure.

4 tbl

FIELD: medicine.

SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.

EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: to correct pathologic changes in the condition of viable offspring under a cytostatic impact the medication glutoxim is introduced to female rats in a dose of 50 mcg/kg 5 days before and 5 days after the introduction of the cytostatic medication vepesid. The latter is introduced once intravenously in a maximal tolerable dose, equal to 30 mg/kg. It has been established that glutoxim can be applied as means for the correction of pathologic changes in the viable offspring of rats, obtained from coupling 3 months after the cytostatic impact.

EFFECT: application of glutoxim as the means of corrective therapy makes it possible to increase efficiency and reduce its side effects.

6 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to versions of a polymeric carrier molecule, a complex of a polymeric carrier with a load, a method of producing a polymeric carrier molecule, a pharmaceutical composition and a vaccine. In one of the versions, the polymeric carrier molecule has the following formula (I): L-P1-S-[S-P2-S]n-S-P3-L and additionally contains in the structure at least one amino acid component (AA)x, wherein AA is an amino acid, x is an integer selected in the range of 1 to 100. If the amino acid component (AA)x is present in the structure, then it is a linker between P1 or P3 and component L. If component L is absent, then at least one amino acid component (AA)x is part of P1 or P3. Components P1 and P3 are different or identical and are a linear or branched chain of a hydrophilic polymer of polyethylene glycol (PEG); P2 is a cationic or polycationic peptide or a protein with length of 3 to 100 amino acids, or a cationic or polycationic polymer with molecular weight of 0.5 kDa to 30 kDa; -S-S is a disulphide bond; L is an optional ligand, n denotes an integer selected from 1 to 50. According to the second version, the polymeric carrier molecule has the formula (Ia) l-P1-S-{[S-P2-S]a[S-(AA)X-S]b}-S-P3-L, where a+b=n, where n equals 1, 2, 3, 4 or 5 to 10; a is an integer selected independent of integer b in the range of 1 to 50, b is an integer selected independent of integer a in the range of 1 to 50. Separate components [S-P2-S] and [S-(AA)x-S] are present in any order in the subformula {[S-P2-S]a[S-(AA)x-S]b}. The complex of the polymeric carrier with a load is formed by the polymeric carrier molecule and a nucleic acid. A pharmaceutical composition and a vaccine include the complex of the polymeric carrier with a load and optionally a pharmaceutically acceptable carrier and/or solvent. Polymeric carrier molecules and the complex of the polymeric carrier with a load are used as a medicinal agent for treating various diseases.

EFFECT: invention enables to obtain a stable polymeric carrier which enables efficient transfection of nucleic acids in cells in vivo and in vitro.

20 cl, 16 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to dermatology and can be used in treating sclerodermia. Versions of the invention provide using naltrexone in treating sclerodermia.

EFFECT: using the inventions enables reducing manifestations of sclerodermia, such as gratuitous synthesis and collagen deposits and fibrosis.

18 cl, 13 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: method is realised by the intravenous allogeneic transplantation of multipotent mesenchymal stromal cells (MMSC) and hematopoietic stem cells (HSC) to laboratory mice one hour after irradiation. HSC are obtained from the placenta of female mice at the 14-day gestation term. MMSC are introduced in a dose of 6.5 mln cells/kg, with HSC being introduced in a dose of 400 thousand cells/kg.

EFFECT: invention makes it possible to extend the arsenal of means, capable of providing the regeneration potential of the spleen tissues, as well as to increase the regeneration of main morphometric spleen indices after exposure to a radiation load.

2 tbl

FIELD: medicine.

SUBSTANCE: introduction of endoscope into duodenum is realised. After that, "tight" filling of choledoch is performed through cholecystostoma with sterile solution, for instance, 0.25% Novocain. After that major duodenal papilla is catheterised and endoscopic papillosphincterotomy is carried out.

EFFECT: method makes it possible to provide effective surgical treatment of cholelithiasis with simultaneous reduction of probability of development of complications due to provision of possibility of fast identification and good visualisation of major duodenal papilla.

1 ex

FIELD: chemistry.

SUBSTANCE: invention refers to thiacalixarene derivatives of general formula I , which can be used as agents for DNA delivery into eukaryotic cells.

EFFECT: there are produced new heterocyclic compounds possessing the effective biological properties.

2 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to neurosurgery, neurooncology, and can be used for the treatment of glial brain tumours of a supratentorial localisation. For this purpose photodithazine in a dose of 1 mg/kg of body weight is introduced to a patient 2 hours before the tumour ablation. After that, surgical access to the tumour is performed. The operation wound is illuminated by blue colour with a wavelength of 400 nm, and the tumour boundaries are determined by means of fluorescence of photodithazine, selectively accumulated in the tumour tissue. The tumour is ablated under control of the tumour luminescence in blue colour with the application of an operation microscope. After that, a flexible light guide from a radiation source with a wavelength of 662 nm and power of 2.0 W with a light dispersing nozzle is placed into the tumour bed and the perifocal zone of the tumour is irradiated. The dose of irradiation is determined by the disappearance of fluorescence.

EFFECT: method provides an increase of the treatment efficiency due to the reliable clear determination of the tumour tissue boundaries with the normal brain substance independent on the malignancy degree and character of the tumour growth, with an increase of its ablation radicality, as well as due to the destruction of cells, located in the perifocal zone.

2 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention aims at pharmaceutical compositions containing a number of microparticles with taste masking, containing high-/low-dose therapeutic agents, at dosage forms containing the above pharmaceutical compositions (such as orally dispersible tablets), and at methods for producing these pharmaceutical compositions and dosage forms.

EFFECT: dosage forms containing the pharmaceutical compositions according to the invention represent the improved homogenous mixtures of the high-dose and low-dose therapeutic agents, which enable controlling the release rate of the therapeutic agent from particles by various ways, as well as flexible correction of dosages when administering the combinations of the therapeutic agents, eg in pain management.

31 cl, 4 dwg, 12 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of microencapsulation, in particular to a method of obtaining microcapsules of medications of a cephalosporin group. The method is characterised by the fact that human serum albumin is used as an envelope for microcapsules, with the addition to a water solution of albumin of a powder of a cephalosporin group preparation in the presence of a surface-active substance E472c, the ratio of quantity of the cephalosporin group preparation to albumin counted per dry substance constitutes from 1:1 to 3:1, the obtained mixture is mixed to the complete dissolution of components with the slow drop-by-drop addition of butanol as the first precipitating agent, and then acetone as the second precipitating agent, the obtained suspension of microcapsules is filtered, washed with acetone, dried in a dessicator, the process of obtaining microcapsules is realised at 25°C.

EFFECT: method provides the simplification and acceleration of the process of obtaining microcapsules of the water-soluble medications of a cephalosporin group in human serum albumin, and reduction of loss in obtaining the microcapsules.

3 ex

FIELD: medicine.

SUBSTANCE: as medications administered are: methotrexate 15 mg per week intake, folic acid 5 mg per week intake, movalis 15 mg per day intake. Laser therapy is administered in differential way depending on degree of disease activity and level of glucosaminoglycanes (GAG). In case of second stage of rheumatoid arthritis - index DAS28 3.2-5.1, level of glucosaminoglycanes 0.510±0.032 g/l, 7 daily procedures of intravenous laser irradiation are carried out. Radiating head KL-VLOK with wavelength 635 nm, power at the end of disposable light guide 1.5 mW, exposure time 15 minutes and laser head KL-VLOK-365 with wavelength 365 nm, power at the end of light guide 1.0 mW, exposure time 5 minutes, are alternated. In case of third degree of activity index DAS28 is higher than 5.1, GAG level is equal or is higher than 0.618±0.069 g/l, 10 procedures are carried out Radiating head KL-VLOK with wavelength 635 nm, power at outlet of disposable light guide 1.5-2.0 mW, exposure time 15 minutes and laser head KL-VLOK-365 nm, power at outlet of disposable light guide 1.0 mW, time of exposure 5 minutes.

EFFECT: method makes it possible to reduce frequency of exacerbations, reduce expression of clinical manifestations, reduce drug load on patient, provides earlier arrest of disease symptoms due to differentiated approach in case of administration of intravenous laser irradiation of blood and its normalising action on GAG indices and reduction of disease activity degree.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of chemical-pharmaceutical industry and medicine. Invention represents application of complex compound of Cu2+ ions with deprotonated (+)-dihydroquercetin (2,3-dihydro-3,5,7-trioxy-2-(3,4-dihydroxyphenyl)-4H-1-benzopyran-4-one) with general formula ML(H2O)n, where M is copper (II), L is deprotonated (+)-dihydroquercetin, namely complex compound of composition CuLH2O, as means with antiviral activity with respect to viruses of flu of strains A/Aichi/2/68 (H3N2) and A/Duck/Potsdam (H5N2).

EFFECT: invention ensures expressed novel properties of complex compound of copper with (+)-dihydroquercetin, possessing direct activity with respect to virus of flu A/Aichi/2/68 (H3N2) and direct virucidal activity with respect to virus A/Duck/Potsdam (H5N2).

1 dwg, 5 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: method involves performing a vitrectomy with removing a posterior hyaloids of a vitreous body, and a laser retinal endocoagulation at wave length 532 nm, emitting power 120-200 mWt, pulse length 0.1-0.2 s, spot diameter 150-200 mcm. A chorioretinal venous anastomosis (CRVA) is induced by exposing the branches of the central vein of the retina to the third-order laser light at wave length 532 nm in a number of 4 coagulated, emitting power 500 mWt, pulse length 1 sec and spot diameter 50 mcm. The vitrectomy is preceded by the intramuscular injections of 12.5% etamylate 4ml and the intravenous administration of 0.5% tranexamic acid 1 g 25-30 minutes before. That is followed by the droplet intravenous administration of an infusion solution containing 0.1% perlinganit 10 ml in 0.9% normal saline 100 ml at an initial rate of 5 mcg/min. The area to be exposed to laser is specified at least in 3 diameters of the disk from the optic disk. The third-order laser applications are applied on the branches of the central vein of the retina in a number from 2 to 4 at wave length 532 nm, emitting power 300-400 mWt, exposure 0.5 s, spot diameter 500 mcm in two points in the proximal and distal direction from the CRVA induction point. Immediately before the CRVA induction, a salt-water infusion flow is increased until the central retinal artery starts pulsating. The surgical management is completed by plugging the vitreal cavity with 20% air-gas mixture SF6.

EFFECT: effective management of the clinical course of the retinal venous thrombosis by considerable reduction of postoperative haemophthalmias.

2 ex

Transdermal plaster // 2553350

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Described is matrix layer, suitable for application in plaster for transdermal delivery, aimed at introduction of biologically active compounds, which includes phosphate compound of tocopherol and polymer carrier. Also described is transdermal plaster and method of its production.

EFFECT: plaster makes it possible to efficiency introduce biologically active compounds.

48 cl, 15 tbl, 13 dwg, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents clinical nutrition for prevention, treatment or relief of one or several symptoms, associated with impairment of metabolism or its disorder, which contains composition of polysaccharide high-viscosity dietary fibre, including viscous fibre mixture or its complex, consisting of from 48% to 90% in wt % of glucomannan, from 5 to 20 % in wt % of xanthan gum and from 5% to 30% in wt % of alginate, as well as, at least, one macroelement, selected from the group, consisting of protein carbohydrate and fat, where clinical nutrition is composed in order to provide dose of composition of polysaccharide high-viscosity dietary fibre from 20 g/day to 35 g/day for time period, effective for prevention, treatment and relief of one or several symptoms, associated with impairment of metabolism or its disorder.

EFFECT: invention ensures extension of arsenal of means, preventing, relieving or treating one or several symptoms, associated with impairment of metabolism or metabolic disease.

14 cl, 6 ex, 20 tbl, 48 dwg

FIELD: medicine.

SUBSTANCE: treating and/or preventing disorders related to overweight and/or obesity, and to methods for preventing or treating disorders related to overweight and/or obesity, including diabetes mellitus is ensured by using a pharmaceutical combination, which contains metformin or its salts, sibutramine or its salts, as well as microcrystalline cellulose in a daily dose as ingredients: sibutramine or its salts 4-17 mg; metformin or its salts 800-2,700 mg; microcrystalline cellulose (25-153.4), or (153.6-158.4), or (158.6-500) mg. The combined use of metformin, sibutramine and microcrystalline cellulose in the declared relations exhibits a synergetic effect, which enables increasing their therapeutic action.

EFFECT: preventive protection and optimisation of treating the patients with overweight or obesity, including type II diabetes mellitus or metabolic syndrome.

6 cl, 2 tbl

FIELD: biotechnology.

SUBSTANCE: increase in biocidal and immunobiological action due to the use of distilled water ionised with silver ions and adding into the composition of succinic, ascorbic, citric acid and aethonium.

EFFECT: increase in biocidal immunobiological properties of the antiseptic-stimulant of Dorogov ASD-2F.

6 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of veterinary medicine, in particular to pharmacology. Combined medication for treating gastrointestinal diseases f calves, accompanied with signs of diarrhoea is characterised by the fact that it contains neomycin sulphate as antibiotic, polyvinylpyrrolodone as detoxicating substance, potassium chloride as cardiac agent, and also contains furazolidone, ethonium and glucose, in specified component ratio.

EFFECT: medication provides 100% efficiency in treatment of affected calves.

1 tbl

FIELD: veterinary science.

SUBSTANCE: a sow should be twice injected with oxytocin and, additionally, intramuscularly about 2-4 h after afterbirth detachment one should introduce clathroprostin at the dosage of 1 ml. The innovation suggested is very efficient in preventing metritis-mastitis-agalactia and endometritis in sows, as well.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

Up!